Onconetix, Inc. financial data

Symbol
ONCO on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 E. Fifth Street, Suite 1900, Cincinnati, OH
State of incorporation
DE
Fiscal year end
December 31
Former names
Blue Water Biotech, Inc. (to 12/18/2023), Blue Water Vaccines Inc. (to 4/20/2023)
Latest financial report
10-Q - Q3 2024 - Dec 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 19.9 % -89.6%
Quick Ratio 1.36 %
Debt-to-equity -317 %
Return On Equity -112 %
Return On Assets -68.7 % -14.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.29M shares -55.5%
Common Stock, Shares, Outstanding 8.31M shares -53.3%
Entity Public Float 13M USD +32.7%
Common Stock, Value, Issued 83 USD -54.6%
Weighted Average Number of Shares Outstanding, Basic 1.31M shares +198%
Weighted Average Number of Shares Outstanding, Diluted 1.31M shares +198%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 700K USD
Revenue from Contract with Customer, Excluding Assessed Tax 407K USD
Cost of Revenue 301K USD
Research and Development Expense 109K USD -50.1%
General and Administrative Expense 8.8M USD +41.8%
Operating Income (Loss) -49.4M USD -187%
Nonoperating Income (Expense) -1.24M USD -44.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -51.7M USD +27.4%
Income Tax Expense (Benefit) -56.4K USD
Net Income (Loss) Attributable to Parent -3.83M USD +28.4%
Earnings Per Share, Basic 6.56 USD/shares +76%
Earnings Per Share, Diluted 6.56 USD/shares +76%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 98K USD
Inventory, Net 122K USD -91.4%
Assets, Current 1.05M USD -89%
Property, Plant and Equipment, Net 69.3K USD +454%
Operating Lease, Right-of-Use Asset 160K USD
Intangible Assets, Net (Excluding Goodwill) 21.4M USD +19.6%
Goodwill 38.9M USD
Assets 61.9M USD +122%
Accounts Payable, Current 4.11M USD +29.5%
Accrued Liabilities, Current 1.34M USD -13.1%
Liabilities, Current 17.4M USD -1.64%
Deferred Income Tax Liabilities, Net 2.87M USD
Operating Lease, Liability, Noncurrent 32.3K USD
Liabilities 20.9M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.01M USD
Retained Earnings (Accumulated Deficit) -86M USD -150%
Stockholders' Equity Attributable to Parent 33.9M USD +231%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 41M USD +301%
Liabilities and Equity 61.9M USD +122%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.23M USD -18.6%
Net Cash Provided by (Used in) Financing Activities 5.21M USD
Net Cash Provided by (Used in) Investing Activities -4.58K USD +87.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 8.33M shares -54.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -90.5K USD +98%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 341K USD -95.5%
Deferred Tax Assets, Valuation Allowance 15.7M USD +248%
Deferred Tax Assets, Gross 17M USD +277%
Payments to Acquire Property, Plant, and Equipment 4.58K USD +152%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -50.6M USD +91.8%
Operating Lease, Liability, Current 128K USD
Deferred Income Tax Expense (Benefit) -122K USD
Deferred Tax Assets, Operating Loss Carryforwards 10.2M USD +242%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 17K USD 0%
Additional Paid in Capital 120M USD +164%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 198K USD
Depreciation, Depletion and Amortization 207K USD +12073%
Deferred Tax Assets, Net of Valuation Allowance 1.3M USD +43275%
Share-based Payment Arrangement, Expense -136K USD -56.7%
Interest Expense 269K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%